SPY001 vs vedolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: α4β7 integrin · full Ulcerative Colitis pipeline
SPY001
Developed by Spyre Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07012395 (registry estimate)
No aligned efficacy figure on record for this race.
vedolizumab · Entyvio
Marketed by Takeda Pharmaceutical Company
NCT00783718 · Phase 3 · completed
Randomized, triple-blind, placebo-controlled, adequately powered (n=895) phase 3 design with hard clinical endpoints (Mayo score-based clinical response/remission), and both primary endpoint comparisons reached statistical significance in the favorable direction (Induction: p<0.0001, RD 21.7%; Maintenance: p<0.0001 for both dose arms vs placebo) — meeting the 'strong' test.
Next expected readout: May 2027 · NCT06581328 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission (Week 52): Percentage of Participants Who Achieved Clinical Remission (Week 52): Adalimumab SC, 160/80/40 mg 22.5% (95% CI 18.5-27.0) vs Vedolizumab IV 300 mg 31.3% (95% CI 26.7-36.2); p=0.0061 (Adalimumab SC, 160/80/40 mg vs Vedolizumab IV 300 mg) (met)
Result source: NCT02497469
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | SPY001 | vedolizumab |
|---|---|---|
| Clinical remission (induction) | —Not reported | 18.3% vs 12.2%+6.1 vs placeboNCT020395051 other result
|
| Clinical remission (maintenance) | —Not reported | 46.2% vs 14.3%+31.9 vs placeboNCT026118304 other results
|
| Clinical response (induction) | —Not reported | 39.6% vs 32.9%+6.7 vs placeboNCT020395051 other result
|
| Endoscopic improvement (induction) | —Not reported | 36.6% vs 30.5%+6.1 vs placeboNCT020395051 other result
|
| Corticosteroid-free remission (maintenance) | —Not reported | 28.9% vs 8.3%+20.6 vs placeboNCT026118304 other results
|
Clinical remission (induction)
- SPY001
- —Not reported
- vedolizumab
- 18.3% vs 12.2%+6.1 vs placeboNCT02039505
1 other result
- 16.9% vs 5.4% NCT00783718
Clinical remission (maintenance)
- SPY001
- —Not reported
- vedolizumab
- 46.2% vs 14.3%+31.9 vs placeboNCT02611830
4 other results
- 41.8% vs 15.9% NCT00783718
- 44.8% vs 15.9% NCT00783718
- 56.1% vs 31% NCT02039505
- 31.3% vs 22.5% NCT02497469
Clinical response (induction)
- SPY001
- —Not reported
- vedolizumab
- 39.6% vs 32.9%+6.7 vs placeboNCT02039505
1 other result
- 47.1% vs 25.5% NCT00783718
Endoscopic improvement (induction)
- SPY001
- —Not reported
- vedolizumab
- 36.6% vs 30.5%+6.1 vs placeboNCT02039505
1 other result
- 40.9% vs 24.8% NCT00783718
Corticosteroid-free remission (maintenance)
- SPY001
- —Not reported
- vedolizumab
- 28.9% vs 8.3%+20.6 vs placeboNCT02611830
4 other results
- 31.4% vs 13.9% NCT00783718
- 45.2% vs 13.9% NCT00783718
- 46.2% vs 20% NCT02039505
- 12.6% vs 21.8% NCT02497469
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SPY001: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. SPY001: 0 of 4 rows · vedolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | vedolizumab |
|---|---|
| Dropout rate | —a NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 56 more results—108 mg SC NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3 29.9%300 mg IV NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 23.1%300 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 22.2%200 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 33.3%150 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —High Dose NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —Low Dose NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 64.6%108 mg NCT02620046 · Phase 3 56.6%108 mg NCT02620046 · Phase 3 —Q2W NCT02620046 · Phase 3 —QW NCT02620046 · Phase 3 —Dose escalation from Q2W to QW NCT02620046 · Phase 3 —Q2W NCT02620046 · Phase 3 —QW NCT02620046 · Phase 3 —Dose escalation from Q2W to QW NCT02620046 · Phase 3 5.5%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 21.7%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg NCT00790933 · Phase 3 · monotherapy 27.1%300 mg NCT04804540 · Phase 4 · registry result, not featured evidence 25.5%300 mg NCT04804540 · Phase 4 · registry result, not featured evidence —RTP: VDZ Dose Optimization: Regime NCT03029143 · Phase 4 · registry result, not featured evidence —RTP: VDZ Dose Optimization: Regime NCT03029143 · Phase 4 · registry result, not featured evidence 9.1%300 mg NCT02559713 · Phase 4 · registry result, not featured evidence 70%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence —300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 71.4%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence —300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 71.4%200 mg NCT03196427 · Phase 2 · registry result, not featured evidence 55.6%200 mg NCT03196427 · Phase 2 · registry result, not featured evidence 75%150 mg NCT03196427 · Phase 2 · registry result, not featured evidence 40%150 mg NCT03196427 · Phase 2 · registry result, not featured evidence 28.6%100 mg NCT03196427 · Phase 2 · registry result, not featured evidence 60%100 mg NCT03196427 · Phase 2 · registry result, not featured evidence —300 mg NCT03138655 · Phase 2 · registry result, not featured evidence 16.7%300 mg NCT03138655 · Phase 2 · registry result, not featured evidence 41.7%300 mg NCT03138655 · Phase 2 · registry result, not featured evidence —200 mg NCT03138655 · Phase 2 · registry result, not featured evidence 30%200 mg NCT03138655 · Phase 2 · registry result, not featured evidence 22.2%200 mg NCT03138655 · Phase 2 · registry result, not featured evidence —150 mg NCT03138655 · Phase 2 · registry result, not featured evidence —150 mg to 300 mg NCT03138655 · Phase 2 · registry result, not featured evidence 25%150 mg NCT03138655 · Phase 2 · registry result, not featured evidence 15.4%150 mg NCT03138655 · Phase 2 · registry result, not featured evidence —100 mg NCT03138655 · Phase 2 · registry result, not featured evidence —100 mg to 200 mg NCT03138655 · Phase 2 · registry result, not featured evidence 18.2%100 mg NCT03138655 · Phase 2 · registry result, not featured evidence 30%100 mg NCT03138655 · Phase 2 · registry result, not featured evidence 97.1%6 mg/kg NCT00619489 · Phase 2 · registry result, not featured evidence 62.2%2 mg/kg NCT00619489 · Phase 2 · registry result, not featured evidence 0%10 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence 0%6 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence 15.4%2 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03329209 · Phase 1 · registry result, not featured evidence 1.6%750 mg NCT01981616 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 56 more results—108 mg SC NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3 4.2%300 mg IV NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 2.2%300 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 7.4%200 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%150 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —High Dose NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —Low Dose NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 9.2%108 mg NCT02620046 · Phase 3 7.6%108 mg NCT02620046 · Phase 3 —Q2W NCT02620046 · Phase 3 —QW NCT02620046 · Phase 3 —Dose escalation from Q2W to QW NCT02620046 · Phase 3 —Q2W NCT02620046 · Phase 3 —QW NCT02620046 · Phase 3 —Dose escalation from Q2W to QW NCT02620046 · Phase 3 4.9%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 15.2%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —300 mg NCT00790933 · Phase 3 · monotherapy 27.1%300 mg NCT04804540 · Phase 4 · registry result, not featured evidence 25.5%300 mg NCT04804540 · Phase 4 · registry result, not featured evidence —RTP: VDZ Dose Optimization: Regime NCT03029143 · Phase 4 · registry result, not featured evidence —RTP: VDZ Dose Optimization: Regime NCT03029143 · Phase 4 · registry result, not featured evidence 9.1%300 mg NCT02559713 · Phase 4 · registry result, not featured evidence 20%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence —300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 42.9%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence —300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 42.9%200 mg NCT03196427 · Phase 2 · registry result, not featured evidence 33.3%200 mg NCT03196427 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03196427 · Phase 2 · registry result, not featured evidence 30%150 mg NCT03196427 · Phase 2 · registry result, not featured evidence 0%100 mg NCT03196427 · Phase 2 · registry result, not featured evidence 40%100 mg NCT03196427 · Phase 2 · registry result, not featured evidence —300 mg NCT03138655 · Phase 2 · registry result, not featured evidence 16.7%300 mg NCT03138655 · Phase 2 · registry result, not featured evidence 33.3%300 mg NCT03138655 · Phase 2 · registry result, not featured evidence —200 mg NCT03138655 · Phase 2 · registry result, not featured evidence 10%200 mg NCT03138655 · Phase 2 · registry result, not featured evidence 11.1%200 mg NCT03138655 · Phase 2 · registry result, not featured evidence —150 mg NCT03138655 · Phase 2 · registry result, not featured evidence —150 mg to 300 mg NCT03138655 · Phase 2 · registry result, not featured evidence 16.7%150 mg NCT03138655 · Phase 2 · registry result, not featured evidence 7.7%150 mg NCT03138655 · Phase 2 · registry result, not featured evidence —100 mg NCT03138655 · Phase 2 · registry result, not featured evidence —100 mg to 200 mg NCT03138655 · Phase 2 · registry result, not featured evidence 18.2%100 mg NCT03138655 · Phase 2 · registry result, not featured evidence 20%100 mg NCT03138655 · Phase 2 · registry result, not featured evidence 20%6 mg/kg NCT00619489 · Phase 2 · registry result, not featured evidence 0%2 mg/kg NCT00619489 · Phase 2 · registry result, not featured evidence —10 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence —6 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence —2 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence —300 mg NCT03329209 · Phase 1 · registry result, not featured evidence 0%750 mg NCT01981616 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 12.4%a NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 56 more results9.4%108 mg SC NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3 11%300 mg IV NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10%300 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.8%200 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0%150 mg NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10.9%High Dose NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 6.4%Low Dose NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —108 mg NCT02620046 · Phase 3 —108 mg NCT02620046 · Phase 3 23%Q2W NCT02620046 · Phase 3 29.9%QW NCT02620046 · Phase 3 30.4%Dose escalation from Q2W to QW NCT02620046 · Phase 3 17.8%Q2W NCT02620046 · Phase 3 20%QW NCT02620046 · Phase 3 36.9%Dose escalation from Q2W to QW NCT02620046 · Phase 3 6.1%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 9.8%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.5%300 mg NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 36.8%300 mg NCT00790933 · Phase 3 · monotherapy 4.2%300 mg NCT04804540 · Phase 4 · registry result, not featured evidence 5.9%300 mg NCT04804540 · Phase 4 · registry result, not featured evidence 14.3%RTP: VDZ Dose Optimization: Regime NCT03029143 · Phase 4 · registry result, not featured evidence 3.7%RTP: VDZ Dose Optimization: Regime NCT03029143 · Phase 4 · registry result, not featured evidence 9.1%300 mg NCT02559713 · Phase 4 · registry result, not featured evidence 40%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 16.7%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 42.9%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 33.3%300 mg NCT03196427 · Phase 2 · registry result, not featured evidence 80%200 mg NCT03196427 · Phase 2 · registry result, not featured evidence 16.7%200 mg NCT03196427 · Phase 2 · registry result, not featured evidence 50%150 mg NCT03196427 · Phase 2 · registry result, not featured evidence 50%150 mg NCT03196427 · Phase 2 · registry result, not featured evidence 0%100 mg NCT03196427 · Phase 2 · registry result, not featured evidence 33.3%100 mg NCT03196427 · Phase 2 · registry result, not featured evidence 33.3%300 mg NCT03138655 · Phase 2 · registry result, not featured evidence —300 mg NCT03138655 · Phase 2 · registry result, not featured evidence —300 mg NCT03138655 · Phase 2 · registry result, not featured evidence 31.6%200 mg NCT03138655 · Phase 2 · registry result, not featured evidence —200 mg NCT03138655 · Phase 2 · registry result, not featured evidence —200 mg NCT03138655 · Phase 2 · registry result, not featured evidence 11.1%150 mg NCT03138655 · Phase 2 · registry result, not featured evidence 16.7%150 mg to 300 mg NCT03138655 · Phase 2 · registry result, not featured evidence —150 mg NCT03138655 · Phase 2 · registry result, not featured evidence —150 mg NCT03138655 · Phase 2 · registry result, not featured evidence 23.5%100 mg NCT03138655 · Phase 2 · registry result, not featured evidence 50%100 mg to 200 mg NCT03138655 · Phase 2 · registry result, not featured evidence —100 mg NCT03138655 · Phase 2 · registry result, not featured evidence —100 mg NCT03138655 · Phase 2 · registry result, not featured evidence 20%6 mg/kg NCT00619489 · Phase 2 · registry result, not featured evidence 8.1%2 mg/kg NCT00619489 · Phase 2 · registry result, not featured evidence 9.1%10 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence 0%6 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence 8.3%2 mg/kg NCT01177228 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03329209 · Phase 1 · registry result, not featured evidence 0%750 mg NCT01981616 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a headache 12.9% (placebo 8.7%) nasopharyngitis 12.9% (placebo 7.4%) colitis ulcerative 9.2% (placebo 13.4%) NCT00783718 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 46 more results108 mg SC colitis ulcerative 11.3% (placebo 25%) nasopharyngitis 10.4% (placebo 19.6%) upper respiratory tract infection 9.4% (placebo 1.8%) NCT02611830 · Phase 3 · combination · Ulcerative Colitis · phase 3 300 mg IV headache 7% nasopharyngitis 7% colitis ulcerative 6.8% NCT02497469 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg upper respiratory tract infection 15.6% pyrexia 5.6% anaemia 4.4% NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 200 mg upper respiratory tract infection 29.6% pyrexia 11.1% clostridium difficile infection 7.4% NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 150 mg anaemia 33.3% gastroenteritis viral 33.3% oral herpes 33.3% NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 High Dose upper respiratory tract infection 17.4% colitis ulcerative 13% anaemia 8.7% NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 Low Dose upper respiratory tract infection 27.7% colitis ulcerative 8.5% influenza 8.5% NCT04779307 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 Dose escalation from Q2W to QW crohn's disease 52% nasopharyngitis 19.6% upper respiratory tract infection 17.6% NCT02620046 · Phase 3 QW colitis ulcerative 23.3% nasopharyngitis 18.3% upper respiratory tract infection 10% NCT02620046 · Phase 3 Dose escalation from Q2W to QW colitis ulcerative 50.8% nasopharyngitis 23.1% anaemia 13.8% NCT02620046 · Phase 3 300 mg viral upper respiratory tract infection 14% (placebo 9.8%) headache 3.7% (placebo 2.4%) nausea 1.2% (placebo 0%) NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg viral upper respiratory tract infection 26.1% (placebo 9.8%) gastroenteritis 6.5% (placebo 0%) headache 6.5% (placebo 2.4%) NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg viral upper respiratory tract infection 43.9% (placebo 9.8%) dental caries 9.8% (placebo 0%) arthralgia 7.3% (placebo 0%) NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg viral upper respiratory tract infection 50.2% (placebo 9.8%) influenza 9.3% (placebo 0%) headache 8.9% (placebo 2.4%) NCT02039505 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 300 mg anaemia 12.5% pyrexia 12.5% headache 8.3% NCT04804540 · Phase 4 · registry result, not featured evidence 300 mg anaemia 7.8% colitis ulcerative 6.9% pyrexia 6.9% NCT04804540 · Phase 4 · registry result, not featured evidence diarrhoea 10.7% headache 10.7% abdominal pain upper 7.1% NCT03029143 · Phase 4 · registry result, not featured evidence colitis ulcerative 11.1% anaemia 7.4% c-reactive protein increased 7.4% NCT03029143 · Phase 4 · registry result, not featured evidence 300 mg crohn's disease 9.1% gastrointestinal motility disorder 9.1% paronychia 9.1% NCT02559713 · Phase 4 · registry result, not featured evidence 300 mg abdominal pain 30% crohn's disease 30% anaemia 20% NCT03196427 · Phase 2 · registry result, not featured evidence 300 mg crohn's disease 66.7% diarrhoea 33.3% oropharyngeal pain 33.3% NCT03196427 · Phase 2 · registry result, not featured evidence 300 mg arthralgia 28.6% colitis ulcerative 28.6% headache 28.6% NCT03196427 · Phase 2 · registry result, not featured evidence 300 mg colitis ulcerative 50% abdominal pain 33.3% diarrhoea 33.3% NCT03196427 · Phase 2 · registry result, not featured evidence 200 mg crohn's disease 40% upper respiratory tract infection 40% abdominal pain 20% NCT03196427 · Phase 2 · registry result, not featured evidence 200 mg pyrexia 66.7% arthralgia 50% colitis ulcerative 50% NCT03196427 · Phase 2 · registry result, not featured evidence 150 mg dehydration 50% ear infection 50% haemoglobin decreased 50% NCT03196427 · Phase 2 · registry result, not featured evidence 150 mg abdominal pain 50% arthralgia 50% asthma 50% NCT03196427 · Phase 2 · registry result, not featured evidence 100 mg anaemia 20% asthma 20% bronchitis 20% NCT03196427 · Phase 2 · registry result, not featured evidence 100 mg abdominal pain upper 33.3% anaemia 33.3% anaemia of chronic disease 33.3% NCT03196427 · Phase 2 · registry result, not featured evidence 300 mg headache 12.5% pharyngitis 12.5% pyrexia 12.5% NCT03138655 · Phase 2 · registry result, not featured evidence 200 mg abdominal pain 15.8% anaemia 15.8% oropharyngeal pain 15.8% NCT03138655 · Phase 2 · registry result, not featured evidence 150 mg ear infection 16.7% bronchitis 11.1% headache 11.1% NCT03138655 · Phase 2 · registry result, not featured evidence 150 mg to 300 mg cough 33.3% dizziness 33.3% headache 33.3% NCT03138655 · Phase 2 · registry result, not featured evidence 100 mg abdominal pain 29.4% arthralgia 11.8% crohn's disease 11.8% NCT03138655 · Phase 2 · registry result, not featured evidence 100 mg to 200 mg diarrhoea 50% vomiting 50% abdominal distension 25% NCT03138655 · Phase 2 · registry result, not featured evidence 6 mg/kg headache 20% nasopharyngitis 20% cough 14.3% NCT00619489 · Phase 2 · registry result, not featured evidence 2 mg/kg nasopharyngitis 13.5% carpal tunnel syndrome 5.4% headache 5.4% NCT00619489 · Phase 2 · registry result, not featured evidence 10 mg/kg headache 18.2% (placebo 11.1%) balance disorder 9.1% (placebo 0%) constipation 9.1% (placebo 11.1%) NCT01177228 · Phase 2 · registry result, not featured evidence 6 mg/kg headache 21.4% (placebo 11.1%) cough 14.3% (placebo 0%) influenza like illness 14.3% (placebo 0%) NCT01177228 · Phase 2 · registry result, not featured evidence 2 mg/kg colitis ulcerative 16.7% (placebo 44.4%) headache 16.7% (placebo 11.1%) nasopharyngitis 16.7% (placebo 11.1%) NCT01177228 · Phase 2 · registry result, not featured evidence 300 mg upper respiratory tract infection 25% leukocyturia 12.5% blood creatine phosphokinase increased 6.3% NCT03329209 · Phase 1 · registry result, not featured evidence 750 mg headache 18.8% (placebo 12.7%) viral upper respiratory tract infection 12.5% (placebo 12.7%) nausea 6.3% (placebo 0%) NCT01981616 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 45 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
vedolizumab
show 1 more result
show 4 more results
show 1 more result
show 1 more result
show 3 more results
show 4 more results
show 2 more results
show 4 more results
show 36 more results
show 1 more result
show 1 more result
show 5 more results
+ 20 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SPY001's landscape · vedolizumab's landscape